Brief: Beam Therapeutics Highlights Progress Across Base Editing Portfolio

Beam Therapeutics

08/01/2024 12:47

Jan 8 (Reuters) - Beam Therapeutics Inc  BEAM.O :
    * BEAM THERAPEUTICS HIGHLIGHTS PROGRESS ACROSS BASE EDITING
PORTFOLIO AND OUTLINES 2024 ANTICIPATED MILESTONES
    * BEAM THERAPEUTICS INC - CASH RUNWAY EXPECTED TO SUPPORT
OPERATING PLANS INTO 2027
    * BEAM THERAPEUTICS INC - INVESTIGATIONAL NEW DRUG (IND)
APPLICATION FOR BEAM-301 ON-TRACK FOR FIRST HALF OF 2024
    * BEAM THERAPEUTICS INC - EUROPEAN CTA SUBMITTED FOR
BEAM-302;
TRIAL INITIATION IN ALPHA-1 ANTITRYPSIN DEFICIENCY PLANNED FOR
FIRST HALF OF 2024
    * BEAM THERAPEUTICS INC - AS OF DECEMBER 31, 2023, BEAM
ESTIMATES
THAT IT HAD $1.2 BILLION IN CASH, CASH EQUIVALENTS AND
MARKETABLE SECURITIES

Source text for Eikon:  ID:nGNX1c37tB 
Further company coverage:  BEAM.O 

 ((Reuters.Briefs@thomsonreuters.com;))